Skip to main content
Displaying 1 - 12 of 26
Display:
12
24
48
Liver Tumours
5
Bayer: Addressing a Changing Treatment Dynamic in HCC: Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Bayer: Addressing a Changing Treatment Dynamic in HCC: Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Bayer: Addressing a Changing Treatment Dynamic in HCC: Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Bayer: Addressing a Changing Treatment Dynamic in HCC: Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Bayer: Addressing a Changing Treatment Dynamic in HCC: Defining Use of TKIs in Selected Patient Populations - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021
View
Cirrhosis & Complications
5
Grifols: Management of decompensated cirrhotic patient: is it time to look beyond? - ILC 2021
View
Cirrhosis & Complications
5
Grifols: Management of decompensated cirrhotic patient: is it time to look beyond? - ILC 2021
View
Pagination
Current page
1
Page
2
Page
3
Next page
next ›
Last page
Last »
©2019 - EASL. All Rights Reserved. Powered by
Enovation
.
Footer menu
Content Access policy
Privacy Policy
Cookie Policy